When a patient with severe pneumonia arrives in the ICU, every hour counts. Standard cultures can take days. They often miss fastidious or atypical organisms. You know the frustration of a negative culture panel while the patient continues to decline. Metagenomic next-generation sequencing (mNGS) offers a way out of that waiting game. It reads all the DNA and RNA in a sample at once. That means you can spot bacteria, viruses, fungi, and parasites in a single test. This guide walks you through the practical steps to make mNGS work in your lab for severe pneumonia cases.

Why Severe Pneumonia Demands a Different Approach

Severe pneumonia is a race. The pathogen could be a typical bacterium like Streptococcus pneumoniae. It could be a virus like influenza or SARS-CoV-2. It could be a fungus like Aspergillus in an immunocompromised host. Standard testing usually requires a separate test for each type. That costs time and sample volume. When a patient is on a ventilator with declining oxygen saturation, you cannot afford to run three different panels and wait for results.

mNGS changes that equation. It casts a wide net. In a single run, it can detect a polymicrobial infection that includes bacteria, a virus, and a fungus all at once. This is especially valuable in hospital-acquired pneumonia where multidrug-resistant organisms are common. The technique also picks up unexpected pathogens that would never have been tested for otherwise.

The Practical Workflow in Six Steps

Implementing mNGS for severe pneumonia does not require a complete lab overhaul. Many hospitals already have the core equipment. Here is the step-by-step process.

1. Collect the right sample at the right time. Bronchoalveolar lavage (BAL) is the gold standard for severe pneumonia. It captures the deep airway environment. If BAL is not possible, endotracheal aspirate or protected brush specimens work. Collect the sample before antibiotics are started if you can. Even a single dose of antibiotics can reduce the microbial DNA signal.

2. Extract high-quality total nucleic acid. You need both DNA and RNA for a complete picture. RNA viruses like influenza and RSV will be missed if you only extract DNA. Use a kit designed for low-biomass respiratory samples. Mechanical lysis with bead beating helps break open tough fungal cell walls.

3. Deplete host DNA. Human cells in a BAL sample can swamp the microbial signal. A host DNA depletion step using saponin or a commercial kit can increase the proportion of pathogen reads by 10 to 50 times. This step is critical for sensitivity.

4. Prepare the sequencing library. This involves fragmentation, end repair, adapter ligation, and PCR amplification. Many commercial kits simplify this into a few hours of hands-on time. Aim for a protocol that takes under four hours.

5. Sequence on a suitable platform. For severe pneumonia, a rapid turnaround matters more than ultra-high depth. Platforms like the Oxford Nanopore MinION or the Illumina iSeq 100 can deliver results within six to twelve hours. Nanopore offers the advantage of real-time data streaming, so you can stop the run once you have enough reads.

6. Run bioinformatics analysis. This is where the raw data becomes a diagnosis. Use a validated pipeline that subtracts human reads, aligns microbial reads to a comprehensive database, and reports a list of potential pathogens with read counts and coverage. The pipeline should flag common contaminants like Cutibacterium acnes.

Common Mistakes That Derail Results

Even a perfect lab protocol can fail if you overlook these issues. Here is a table of the most frequent problems and how to fix them.

Mistake	Consequence	Fix
Using a throat swab instead of a lower respiratory sample	Low sensitivity for lung pathogens	Always use BAL, mini-BAL, or endotracheal aspirate
Skipping host DNA depletion	99% of reads are human; pathogen signal is buried	Add a host depletion step before extraction
Running only DNA extraction	Miss RNA viruses like SARS-CoV-2 and influenza	Use a total nucleic acid extraction kit
Relying on a generic database	Miss novel or locally circulating strains	Use a curated respiratory pathogen database updated quarterly
Ignoring the background contaminant list	Report false positives from lab reagents	Maintain a running list of common contaminants in your lab

Building a Bioinformatics Pipeline That Works

You do not need to be a bioinformatician to get good results. But you do need a pipeline that is tuned for respiratory samples. Here is what a good one includes.

• Human read removal using a tool like Minimap2 or Bowtie2 against the human genome.
• Quality filtering to remove low-complexity and short reads.
• Alignment to a curated pathogen database. The NCBI RefSeq database is a good start, but a respiratory-specific subset reduces noise.
• Taxonomic classification using a tool like Kraken2 or Centrifuge.
• A reporting threshold. For severe pneumonia, a common rule is at least 10 unique reads per million total reads for a bacterial pathogen, and at least 1 read for a virus.

Expert Advice: “Start with a positive control. Run a mock community of known respiratory pathogens through your entire workflow. This tells you exactly where your sensitivity and specificity stand before you touch a patient sample.” — Dr. Maria Chen, Director of Clinical Microbiology at a large academic medical center.

When mNGS Shines and When It Stumbles

mNGS is not a replacement for all traditional testing. It is a complement. Use it in these scenarios.

• Immunocompromised patients. A transplant recipient with a fever of unknown origin. mNGS can pick up CMV, Pneumocystis jirovecii, and a bacterial superinfection in one run.
• Negative culture after 48 hours. The patient looks sick, but the cultures are clean. mNGS often finds an anaerobic or fastidious organism.
• Outbreak investigation. A cluster of severe pneumonia cases on the same ward. mNGS can genotype the strain and suggest a common source.

But be careful with these limitations.

• Quantification is rough. mNGS gives relative abundance, not a colony count. Do not use it to decide antibiotic dosing.
• Contaminants are everywhere. Reagents, the lab environment, and even the phlebotomist’s skin can contribute reads. A negative control is mandatory with every batch.
• Turnaround time is not instant. Even with a fast protocol, you are looking at 8 to 24 hours. For a patient crashing in the ICU, a Gram stain and antigen test are still faster.

Integrating Results into Clinical Decision Making

Getting a report is only half the battle. The real value comes from how you use it. Here are some practical tips.

• Present results in a clinical context. A list of species names is not helpful. The report should flag each organism as a high, medium, or low confidence pathogen based on read count, coverage, and clinical relevance.
• Correlate with the patient’s presentation. If the report shows Legionella pneumophila but the patient has no urinary antigen, consider a repeat sample or a different testing method.
• Discuss results with the ID team. mNGS can detect colonizers and commensals alongside true pathogens. A clinician who knows the patient’s history is essential for interpretation.
• Use it to de-escalate therapy. If mNGS shows only a single pathogen, you can narrow broad-spectrum antibiotics. This is one of the strongest arguments for implementing the technology.

For more on how new diagnostic tools are shaping the field, take a look at our article on innovative diagnostic tools transforming respiratory disease management.

What Your Lab Needs to Get Started

You do not need a massive budget. Many labs already have a thermocycler and a centrifuge. Here is the minimum shopping list.

• A DNA/RNA extraction kit with bead beating.
• A host depletion kit or a protocol using saponin.
• A library preparation kit (many options exist for under $50 per sample).
• A sequencer. The Oxford Nanopore Flongle or MinION is the most affordable entry point.
• A laptop or small server for bioinformatics. A standard laptop can run a cloud-based pipeline.

The total cost per sample can be under $150 for consumables. That is competitive with sending out multiple PCR panels and cultures.

Looking Ahead: Where the Field Is Going in 2026

The technology is moving fast. Here are three trends that will affect your lab soon.

• Automated sample-to-result systems. Companies like Day Zero Diagnostics and IDbyDNA are developing closed systems that reduce hands-on time to under 10 minutes.
• Real-time antimicrobial resistance prediction. New algorithms can scan for resistance genes directly from the sequencing data. This could give you a resistance profile alongside the pathogen ID.
• Integration with the electronic health record. Some hospitals are already piping mNGS results directly into the patient chart alongside microbiology data.

These advances will make mNGS easier to use, but the core workflow described here will remain the backbone. For a broader view of how respiratory care is evolving, check out our piece on emerging medical technologies transforming respiratory care in 2026.

A Final Word on Getting Started

You do not have to perfect the entire workflow before your first patient case. Start with a pilot. Run a few known positive BAL samples through the process. Compare the results to your standard culture and PCR results. Learn where your pipeline adds value and where it creates noise. Share your early findings with your infectious disease colleagues. Once they see a case where mNGS caught something the standard panel missed, you will have buy-in. That is the moment the technology stops being a research project and becomes a clinical tool.

Go ahead and set up that first mock run this week. The patients who need it most are waiting.